Abstract
Purpose
To evaluate the frequency and prognostic importance of neuroendocrine differentiation (NED) in Japanese breast cancer patients.
Methods
We used standard immunohistochemical techniques to examine 50 patients who underwent resection of breast cancer between 1988 and 1993 at the Department of Surgery II, Nagoya University Hospital, for NED, defined as positive reactivity for four markers: neuron-specific enolase (NSE), synaptophysin, CD57, and chromogranin A (CGA). Neuroendocrine differentiation was defined by the presence of at least one marker including CGA, CD57, and synaptophysin, or at least two markers when one was positive for NSE.
Results
Neuroendocrine differentiation was found in 13 (26%) of the 50 patients examined. There were no significant differences in the distribution of patients with positive or negative NED in terms of age, menopausal status, tumor size, lymph node metastasis, histological grade, ER, PgR, and HER2. We calculated the cumulative survival rates of patient groups according to NED status, and found no significant difference in overall or disease-free survival between patients with and those without NED.
Conclusion
Neuroendocrine differentiation was identified in a subset (26%) of Japanese breast cancer patients, but this appeared to have no relationship with established prognostic factors or patient outcome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schnitt SJ, Guidi AJ. Invasive carcinoma with neuroendocrine differentiation. In: Harris R, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 443–465.
Tezel E, Nagasaka T, Nomoto S, Sugimoto H, Nakao A. Neuroendocrine-like differentiation in patients with pancreatic carcinoma. Cancer 2000;89:2230–2236.
Tezel E, Nagasaka T, Tezel G, Nakao A. Characterization of scattered neuroendocrine cells in ductal carcinomas of the pancreas. Pancreas 2001;25:136–141.
McWilliam LJ, Manson C, George NJR. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol 1997;80:287–290.
Weinstein MH, Partin AW, Veltri RW, Epstein JL. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostectomy. Hum Pathol 1996;27:683–687.
Segawa N, Mori I, Utsunomiya H, Nakamura M, Nakamura Y, Shan L, et al. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 2001;51:452–459.
Arends JW, Wiggers T, Verstijnen K, Bosman FT. The occurrence and clinicopathological significance of serotonin immunoreactive cells in large bowel carcinoma. J Pathol 1986;149:97–102.
Hamada Y, Oishi A, Shoji T, Takada H, Yamamura M, Hioki K, et al. Endocrine cells and prognosis in patients with colorectal carcinoma. Cancer 1992;69:2641–2646.
Berendsen HH, de Leij L, Poppema S, Postmus PE, Boes A, Sluiter HJ, et al. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 1989;7:1614–1620.
Hong SM, Kim MJ, Pi DY, Jo D, Yu E, Ro JY. Neuroendocrine differentiation in extrahepatic bile duct carcinomas and its prognostic significance. Hum Pathol 2005;36:732–740.
Sapino A, Papotti M, Righi L, Cassoni P, Chiusa L, Bussolati G. Clinical significance of neuroendocrine carcinoma of the breast. Ann Oncol 2001;12:S115–S117.
Bofin AM, Qvigstad G, Waldum C, Waldum HL. Neuroendocrine differentiation in carcinoma of the breast. Tyramide signal amplification discloses chromogranin A-positive tumour cells in more breast tumours than previously realized. APMIS 2002;110:658–664.
Sapino A, Bussolati G. Is detection of endocrine cells in breast adenocarcinoma of diagnostic and clinical significance? Histopathology 2002;40:211–214.
Miremadi A, Pinder SE, Lee AH, Bell JA, Paish EC, Wencyk P, et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology 2002;40:215–222.
Günhan-Bilgen I, Zekioglu O, Ustün EE, Memis A, Erhan Y. Neuroendocrine differentiated breast carcinoma: imaging features correlated with clinical and histopathological findings. Eur Radiol 2003;13:788–793.
Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol 2003;34:1001–1008.
Nesland JM, Lunde S, Holm R, Johannessen JV. Electron microscopy and immunostaining of the normal breast and its benign lesions. A search for neuroendocrine cells. Histol Histopathol 1987;2:73–77.
Fetissof F, Dubois MP, Arbeille-Brassart B, Lansac J, Jobard P. Argyrophilic cells in mammary carcinoma. Hum Pathol 1983;14:127–134.
Maluf HM, Koerner FC. Carcinomas of the breast with endocrine differentiation: a review. Virchows Arch 1994;425:449–457.
Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003. p. 13–59.
Kawasaki T, Nakamura S, Sakamoto G, Murata S, Tsunoda-Shimizu H, Suzuki K, et al. Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast — comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases. Histopathology 2008;53:288–298.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sawaki, M., Yokoi, K., Nagasaka, T. et al. Prognostic importance of neuroendocrine differentiation in Japanese breast cancer patients. Surg Today 40, 831–835 (2010). https://doi.org/10.1007/s00595-009-4179-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00595-009-4179-2